Stockscreener 앱 받기
0.50
16.17%
0.0696
시간 외 거래:
.48
-0.02
-4.00%
전일 마감가:
$0.4304
열려 있는:
$0.49
하루 거래량:
7.34M
Relative Volume:
1.37
시가총액:
$76.69M
수익:
$3,000
순이익/손실:
$-122.20M
주가수익비율:
-0.2201
EPS:
-2.272
순현금흐름:
$-86.81M
1주 성능:
+12.38%
1개월 성능:
-1.19%
6개월 성능:
-50.50%
1년 성능:
-59.35%
1일 변동 폭
$0.455
$0.50
1주일 범위
$0.4167
$0.50
52주 변동 폭
$0.3772
$3.03
Fractyl Health Inc Stock (GUTS) Company Profile
명칭
Fractyl Health Inc
전화
781-902-8800
주소
3 VAN DE GRAAFF DRIVE, BURLINGTON
Compare GUTS vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GUTS
Fractyl Health Inc
|
0.50 | 66.01M | 3,000 | -122.20M | -86.81M | -2.272 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Fractyl Health Inc Stock (GUTS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-15 | 개시 | H.C. Wainwright | Buy |
| 2025-08-28 | 개시 | Ladenburg Thalmann | Buy |
| 2024-02-28 | 개시 | Evercore ISI | Outperform |
| 2024-02-27 | 개시 | BofA Securities | Buy |
| 2024-02-27 | 개시 | Morgan Stanley | Overweight |
모두보기
Fractyl Health Inc 주식(GUTS)의 최신 뉴스
BofA Securities Maintains Fractyl Health(GUTS.US) With Buy Rating - Moomoo
Fractyl Health (GUTS) Stock Jumps 21% After Hours: Here's What You Should Know - Benzinga
Fractyl Health Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Fractyl Health Inc (GUTS) Q4 2025 Earnings Call Highlights: Navigating Financial Challenges ... By GuruFocus - Investing.com Canada
Fractyl Health outlines 2026 De Novo submission plans with pivotal Revita data expected in early Q4 - MSN
Disease-Modifying Therapies for Obesity and Type 2 Diabetes: Revita and Rejuva Pipeline Overview - Minichart
Fractyl Health Inc’s 2025 Q4 Call: CPT Code Timing, Regulatory Readiness, and Ablation Targets Don’t Align - Bitget
GUTS: Pivotal study enrollment complete; Revita advances toward key 2026 data and de novo submission - TradingView
Fractyl Health Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Fractyl Health Q4 2025 sees cost cut, stock dips - Investing.com
Fractyl Health (NASDAQ:GUTS) Posts Narrower-Than-Expected Loss Ahead of Pivotal Trial Readout - ChartMill
FRACTYL HEALTH ($GUTS) Releases Q4 2025 Earnings - Quiver Quantitative
Fractyl Highlights Revita Progress and 2025 Financial Results - TipRanks
Fractyl Health (NASDAQ:GUTS) Releases Earnings Results, Misses Expectations By $0.13 EPS - MarketBeat
Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates - The Manila Times
Fractyl Health 2025 10-K: $0M Revenue, Net Loss $140.954M - TradingView
Fractyl Health (NASDAQ: GUTS) outlines Revita device and Rejuva gene therapy plans - Stock Titan
Fractyl Health (Nasdaq: GUTS) widens 2025 loss but advances pivotal Revita - Stock Titan
If You Invested $1,000 in Fractyl Health (GUTS) - Stock Titan
Fractyl Health, Inc. (GUTS) loses 77.6% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Fractyl Health (NASDAQ:GUTS) - intelligentinvestor.com.au
H.C. Wainwright Maintains a Buy Rating on Fractyl Health, Inc. (GUTS) with an $8 Price Target - Insider Monkey
Fractyl Health, Inc. (GUTS) moves to buy: Rationale behind the upgrade - MSN
Fractyl Health Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
Fractyl Health (Nasdaq: GUTS) faces Nasdaq minimum bid-price warning - Stock Titan
Portfolio Shifts: Is Fractyl Health Inc undervalued by DCF analysis2026 Chart Watch & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Fractyl Health to report fourth quarter and full year 2025 financial results and provide business updates on March 24, 2026 - marketscreener.com
Fractyl Health To Report Fourth Quarter And Full Year 2025 Financial Results And Provide Business Updates On March 24, 2026 - TradingView
Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026 - The Manila Times
Investment Report: What is the dividend yield of Fractyl Health Inc2026 Valuation Update & Growth Oriented Trade Recommendations - baoquankhu1.vn
Fractyl Health, Inc. (GUTS) Initiates Purchase: Reasons for the Rating Increase - Bitget
Rosalind Advisors Inc. Takes Position in Fractyl Health, Inc. $GUTS - MarketBeat
Does Fractyl Health Inc have pricing powerMarket Growth Review & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Fractyl Health announces proposed public offering - MSN
Aug Reactions: What is the dividend yield of Fractyl Health IncWeekly Stock Recap & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Fractyl Health, Inc. (NASDAQ:GUTS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
GUTS Technical Analysis & ETF Price Forecast - Intellectia AI
GUTS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Fractyl Health Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Fractyl Completes Randomization in REMAIN-1 Revita Trial - The Globe and Mail
Fractyl Health completes randomization in Remain-1 pivotal cohort of Revita® - marketscreener.com
Fractyl Health Completes Randomization In Remain-1 Pivotal Cohort Of Revita® - TradingView
Fractyl Health completes randomization in REMAIN-1; topline 6-month data due early Q4 2026 - TradingView
Fractyl Health (GUTS) hits Revita pivotal trial milestone, eyes 2026 FDA filing - Stock Titan
Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance - GlobeNewswire
Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita for Post-GLP-1 Weight Maintenance - Bitget
GUTS SEC FilingsFractyl Health 10-K, 10-Q, 8-K Forms - Stock Titan
Fractyl Health, Inc. (GUTS) Loses 77.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Finviz
Fractyl Health (GUTS) Projected to Post Quarterly Earnings on Monday - MarketBeat
Should I buy Fractyl Health, Inc. (GUTS) - Zacks Investment Research
GUTSFractyl Health Latest Stock News & Market Updates - Stock Titan
Fractyl Health Inc (GUTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):